Hyaluronidase Injections Into the Fingers for Tight Skin in Systemic Sclerosis
Tests hyaluronidase injected into the fingers of adults with systemic sclerosis.
Plain-language title generated from the registry record
Registry title: Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
Key facts
- Where
- Charleston, United StatesSee the site
- Phase
- Early phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07697274, who can take part
Where in United States
- Medical University of South CarolinaCharleston, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Medical University of South Carolina
- Trial code
- NCT07697274
- Record updated
- 16 October 2026
- Original description
Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.Read full original descriptionShow less
Digital Intradermal Hyaluronidase for Sclerodactyly in Systemic Sclerosis
Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.
Inclusion: Age ≥18 and <60 years; Diagnosis of systemic sclerosis; Presence of sclerodactyly; Ability to provide informed consent.
Exclusion: Recent changes in systemic immunomodulatory therapy; Known hypersensitivity to hyaluronidase; Unstable systemic disease; Conditions interfering with safe digital injections; Pregnancy or breastfeeding.